Abstract
In a single-center, randomized study, zanamivir (Relenza) concentrations in induced sputum samples and nasal washings of healthy adults following oral inhalation were measured. Concentrations in sputum exceeded the median viral neuraminidase 50% inhibitory concentration at 6, 12, and 24 h, and those in nasal washings did so at 6 and 12 h. There were no zanamivir-related adverse events or laboratory abnormalities.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Administration, Inhalation
-
Adult
-
Antiviral Agents / adverse effects
-
Antiviral Agents / pharmacokinetics*
-
Female
-
Guanidines
-
Humans
-
Male
-
Nasal Lavage Fluid
-
Neuraminidase / antagonists & inhibitors
-
Orthomyxoviridae / drug effects
-
Orthomyxoviridae / enzymology
-
Pyrans
-
Respiratory System / metabolism*
-
Sialic Acids / adverse effects
-
Sialic Acids / pharmacokinetics*
-
Sputum / metabolism
-
Zanamivir
Substances
-
Antiviral Agents
-
Guanidines
-
Pyrans
-
Sialic Acids
-
Neuraminidase
-
Zanamivir